Anderlé MPoint@Anderle

5D

Looks quite reasonable $NWRN:

+ EV / Sales (5.29)
+ Gross Margin TTM (98.26%)
+ Rule-of-40 Score TTM (432.88%)
+ Sales Growth TTM (467.18%)
+ PEG TTM (0.04)
+ Return on equity LJ (1086.63%)
+ EBIT margin LJ (50.93%)

- Debt ratio (34.68)
- Equity ratio LJ (2.28%) ✌🏻

Show original (German)

Like•

👍

22

•Answer

PiHu@PiHu

5D

@Anderle huhu, where did you get the data so quickly? :)

Show original (German)

Like•

👍

11

•Answer

Anderlé MPoint@Anderle

5D

@PiHu I'm registered at https://aktien.guide/ (premium account) I think the site is really great and very clear ✌🏻

Show original (German)

Like•

👍

33

•Answer

Sam M.@Sam_Mumm

5D

@Anderle There is always the risk that Evenamide will not be approved and then the price will plummet.

Show original (German)

Like•

👍

11

•Answer

Anderlé MPoint@Anderle

5D

@Sam_Mumm Correct, the risk exists for all pharmaceutical and biotechnology companies.

Show original (German)

Like•

👍

22

•Answer